Clinical Trial Update: Ixabepilone in Treating Young Patients With Refractory Solid Tumors [Phase 2]

View source ↗

Summary

Phase 2 trial update on ixabepilone in young patients with refractory solid tumors. The study status is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ewing Sarcoma
• Neuroblastoma
• Osteosarcoma
• Rhabdomyosarcoma
• Soft Tissue Sarcoma
• Synovial Sarcoma
• Wilms Tumor

Drugs mentioned

• Ixabepilone (ixabepilone)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Adult Rhabdomyosarcoma, Adult Synovial Sarcoma | Phase 2 | Status: COMPLETED